Denali Therapeutics Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purcha...
December 12 2017 - 4:10PM
Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the closing
of its initial public offering of 15,972,221 shares of its common
stock at a price to the public of $18.00 per share, which includes
the exercise in full by the underwriters of their option to
purchase up to 2,083,333 additional shares.
Goldman Sachs & Co. LLC, Morgan Stanley and J.P. Morgan
acted as joint book-running managers for the offering, and Evercore
Group L.L.C. acted as lead manager for the offering.
The offering was made only by means of a prospectus. A copy of
the final prospectus relating to this offering may be obtained
from:
Goldman Sachs & Co. LLC, Attention: Prospectus Department,
200 West Street, New York, NY 10282, telephone: 1-866-471-2526,
fax: 212-902-9316, email: prospectusgroup-ny@ny.email.gs.com;
Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180
Varick Street, 2nd Floor, New York, NY 10014; or J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, telephone: 1-866-803-9204 or by
email: prospectus-eq_fi@jpmchase.com.
A registration statement relating to the offering was declared
effective by the United States Securities and Exchange Commission
(“SEC”) on December 7, 2017. Copies of the registration statement
can be accessed through the SEC’s website at www.sec.gov. This
press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor will there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful before registration or
qualification under the securities laws of that state or
jurisdiction.
About Denali
Denali is a biopharmaceutical company developing
a broad portfolio of therapeutic candidates for neurodegenerative
diseases. Denali is based in South San Francisco.
CONTACT:
Lizzie Hyland(646)
495-2706lhyland@gpg.com
or
Morgan Warners(202)
295-0124mwarners@gpg.com
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jul 2023 to Jul 2024